Structure and stability of symptoms in first episode psychosis: a longitudinal network approach.


Journal

Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664

Informations de publication

Date de publication:
06 11 2021
Historique:
received: 02 03 2021
accepted: 20 10 2021
revised: 21 09 2021
entrez: 7 11 2021
pubmed: 8 11 2021
medline: 1 2 2022
Statut: epublish

Résumé

Early psychosis is characterised by heterogeneity in illness trajectories, where outcomes remain poor for many. Understanding psychosis symptoms and their relation to illness outcomes, from a novel network perspective, may help to delineate psychopathology within early psychosis and identify pivotal targets for intervention. Using network modelling in first episode psychosis (FEP), this study aimed to identify: (a) key central and bridge symptoms most influential in symptom networks, and (b) examine the structure and stability of the networks at baseline and 12-month follow-up. Data on 1027 participants with FEP were taken from the National EDEN longitudinal study and used to create regularised partial correlation networks using the 'EBICglasso' algorithm for positive, negative, and depressive symptoms at baseline and at 12-months. Centrality and bridge estimations were computed using a permutation-based network comparison test. Depression featured as a central symptom in both the baseline and 12-month networks. Conceptual disorganisation, stereotyped thinking, along with hallucinations and suspiciousness featured as key bridge symptoms across the networks. The network comparison test revealed that the strength and bridge centralities did not differ significantly between the two networks (C = 0.096153; p = 0.22297). However, the network structure and connectedness differed significantly from baseline to follow-up (M = 0.16405, p = <0.0001; S = 0.74536, p = 0.02), with several associations between psychosis and depressive items differing significantly by 12 months. Depressive symptoms, in addition to symptoms of thought disturbance (e.g. conceptual disorganisation and stereotyped thinking), may be examples of important, under-recognized treatment targets in early psychosis, which may have the potential to lead to global symptom improvements and better recovery.

Identifiants

pubmed: 34743179
doi: 10.1038/s41398-021-01687-y
pii: 10.1038/s41398-021-01687-y
pmc: PMC8572227
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

567

Subventions

Organisme : Chief Scientist Office
ID : CAF/19/04
Pays : United Kingdom

Informations de copyright

© 2021. The Author(s).

Références

Schizophr Res. 1990 Jul-Aug;3(4):247-51
pubmed: 2278986
Schizophr Bull. 2017 Mar 1;43(2):240-244
pubmed: 27421793
Eur Psychiatry. 2017 Feb;40:65-75
pubmed: 27992836
J Anxiety Disord. 2017 Jan;45:49-59
pubmed: 27936411
Br J Psychiatry. 2017 Oct;211(4):198-204
pubmed: 28882827
Schizophr Bull. 2021 Jan 23;47(1):249-258
pubmed: 32634220
Acta Psychiatr Scand. 2018 Oct;138(4):289-299
pubmed: 29974451
Soc Psychiatry Psychiatr Epidemiol. 2006 Jun;41(6):423-8
pubmed: 16572272
BMJ. 2004 Nov 6;329(7474):1067
pubmed: 15485934
J Am Acad Child Adolesc Psychiatry. 2011 Jul;50(7):669-80
pubmed: 21703494
Psychiatry Res. 2014 Feb 28;215(2):314-22
pubmed: 24355686
JAMA Psychiatry. 2018 Nov 1;75(11):1156-1172
pubmed: 30267047
Early Interv Psychiatry. 2014 Feb;8(1):59-67
pubmed: 23347742
Schizophr Bull. 2017 Jan;43(1):187-196
pubmed: 27165690
Schizophr Bull. 2015 Jul;41(4):951-62
pubmed: 25180313
Arch Gen Psychiatry. 2001 Jul;58(7):663-8
pubmed: 11448373
Schizophr Res. 2016 Dec;178(1-3):17-22
pubmed: 27617414
Clin Psychol Rev. 2007 May;27(4):409-24
pubmed: 17222489
Lancet Psychiatry. 2014 Jun;1(1):23-33
pubmed: 26360400
Psychol Methods. 2018 Dec;23(4):617-634
pubmed: 29595293
Psychother Psychosom. 2019;88(2):71-83
pubmed: 30889609
Acta Psychiatr Scand. 2006 Sep;114(3):177-86
pubmed: 16889588
Schizophr Bull. 1986;12(3):373-93
pubmed: 3764358
Br J Psychiatry Suppl. 1998;172(33):53-9
pubmed: 9764127
Psychiatry Res. 2020 Jan 21;285:112806
pubmed: 32007658
Innov Clin Neurosci. 2017 Dec 1;14(11-12):59-67
pubmed: 29410938
Schizophr Res. 2016 Dec;178(1-3):29-34
pubmed: 27639419
PLoS One. 2014 Nov 26;9(11):e112734
pubmed: 25427156
Schizophr Bull. 2021 Apr 29;47(3):604-614
pubmed: 33410487
Schizophr Bull. 2020 Jul 8;46(4):964-970
pubmed: 31989151
Schizophr Res. 2018 Mar;193:232-239
pubmed: 28844638
Pharmgenomics Pers Med. 2016 Nov 07;9:117-129
pubmed: 27853387
Arch Gen Psychiatry. 2010 Dec;67(12):1230-7
pubmed: 21135323
Eur Arch Psychiatry Clin Neurosci. 2005 Jun;255(3):202-12
pubmed: 15995904
Behav Res Methods. 2018 Feb;50(1):195-212
pubmed: 28342071
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
NPJ Schizophr. 2020 Dec 15;6(1):40
pubmed: 33319805
Schizophr Bull. 2019 Oct 24;45(6):1319-1330
pubmed: 30649527
PLoS One. 2016 Sep 19;11(9):e0162811
pubmed: 27643994
World Psychiatry. 2020 Feb;19(1):81-91
pubmed: 31922687
Br J Clin Psychol. 2006 Nov;45(Pt 4):561-77
pubmed: 17076964
Br J Math Stat Psychol. 2020 May;73(2):187-212
pubmed: 31206621
PLoS One. 2015 Oct 27;10(10):e0141420
pubmed: 26505477
Can J Psychiatry. 2019 Oct;64(10):680-685
pubmed: 31434513
J Psychiatr Res. 2021 Aug;140:373-380
pubmed: 34144441
Schizophr Bull. 2017 Jan;43(1):122-132
pubmed: 27384055
Medicina (Kaunas). 2020 Nov 24;56(12):
pubmed: 33255489
Ann Appl Stat. 2016 Mar;10(1):418-450
pubmed: 27213023
Adv Methods Pract Psychol Sci. 2019 Mar 1;2(1):55-76
pubmed: 31463424
Multivariate Behav Res. 2021 Mar-Apr;56(2):353-367
pubmed: 31179765
Psychol Med. 2012 Apr;42(4):769-80
pubmed: 21995856
Lancet Psychiatry. 2018 Jun;5(6):515-526
pubmed: 29678679
J Clin Psychopharmacol. 2010 Aug;30(4):446-9
pubmed: 20631562
Schizophr Res Treatment. 2012;2012:916198
pubmed: 22966451

Auteurs

Siân Lowri Griffiths (SL)

Institute for Mental Health, University of Birmingham, Birmingham, UK. s.l.griffiths@bham.ac.uk.

Samuel P Leighton (SP)

Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.

Pavan Kumar Mallikarjun (PK)

Institute for Mental Health, University of Birmingham, Birmingham, UK.

Georgina Blake (G)

College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

Linda Everard (L)

Birmingham and Solihull Mental Health Foundation Trust, Birmingham, UK.

Peter B Jones (PB)

Department of Psychiatry, University of Cambridge and CAMEO, Cambridge and Peterborough NHS Foundation Trust, Cambridge, UK.

David Fowler (D)

Department of Psychology, University of Sussex, Brighton, UK.

Joanne Hodgekins (J)

Norwich Medical School, University of East Anglia, Norwich, UK.

Tim Amos (T)

Academic Unit of Psychiatry, University of Bristol, Bristol, UK.

Nick Freemantle (N)

Institute of Clinical Trials and Methodology, University College London, London, UK.

Vimal Sharma (V)

Early Intervention Service, Cheshire and Wirral NHS Foundation Trust, Liverpool, UK.

Max Marshall (M)

Lancashire Care NHS Foundation Trust, Preston, UK.

Paul McCrone (P)

Institute for Life Course Development, University of Greenwich, London, UK.

Swaran P Singh (SP)

Mental Health and Wellbeing Warwick Medical School, University of Warwick, Coventry, UK.

Max Birchwood (M)

Mental Health and Wellbeing Warwick Medical School, University of Warwick, Coventry, UK.

Rachel Upthegrove (R)

Institute for Mental Health, University of Birmingham, Birmingham, UK.
College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH